Micromet has entered into a collaboration agreement with Amgen for the research of BiTE antibodies against three undisclosed solid tumor targets. Amgen will have the right to pursue development and commercialization of two of these targets. Amgen will pay $14 million up front, with clinical and commercial milestones in multiple indications and tumor types of as much as $475 million, in addition to royalties on sales. Micromet is eligible to receive an additional payment upon initiation of a sec...